id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0118-0006,FDA,FDA-2016-E-0118,Determinations of Regulatory Review Periods for Purpose of Patent Extensions: NATPARA,Notice,Determinations,2017-06-15T04:00:00Z,2017,6,2017-06-15T04:00:00Z,2017-08-15T03:59:59Z,2017-06-15T13:42:11Z,2017-12359,0,0,09000064826dbb91
FDA-2016-E-0118-0005,FDA,FDA-2016-E-0118,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T15:32:18Z,,0,0,09000064826a1cb2